Skip to main content
Sumita Roy-Ghanta on Muck Rack

Sumita Roy-Ghanta

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sumita

Contact Sumita, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7

|
By Theodoros Papathanasiou, Xi Chen, Geraldine Ferron-Brady, Astrid McKeown, Sumita Roy-Ghanta, Lydia Eccersley, Ravi Kasinathan, Nashita Patel
| Nature Verified
Abstract Belantamab mafodotin, bortezomib and dexamethasone (BVd) demonstrated clinical activity in the phase I/II DREAMM-6 (Arm B) study and significant clinical benefit in the phase III DREAMM-7 study for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy.
Open in Who Shared Issue with article?
See all 1 articles